Home/Filings/4/0000950170-24-015259
4//SEC Filing

Farwell Wildon 4

Accession 0000950170-24-015259

CIK 0001818794other

Filed

Feb 13, 7:00 PM ET

Accepted

Feb 14, 4:27 PM ET

Size

5.2 KB

Accession

0000950170-24-015259

Insider Transaction Report

Form 4
Period: 2024-02-12
Farwell Wildon
Chief Medical Officer
Transactions
  • Sale

    Common Stock

    2024-02-12$25.07/sh5,493$137,710163,503 total
Footnotes (3)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 14, 2023.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
  • [F3]Includes 145,667 unvested RSUs.

Documents

1 file

Issuer

Dyne Therapeutics, Inc.

CIK 0001818794

Entity typeother

Related Parties

1
  • filerCIK 0001847941

Filing Metadata

Form type
4
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 4:27 PM ET
Size
5.2 KB